PYC Physiomics Plc

TIDMPYC

Physiomics PLC

28 April 2020

28 April 2020

Physiomics plc

("Physiomics") or (the "Company")

Conference attendance and presentation

Physiomics attends BioTrinity 2020

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour(TM) technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it is participating in the BioTrinity 2020 conference which is being held digitally this week. In lieu of face to face meetings, the Company has made a pre-recorded presentation which is available to all conference attendees, the slides for which can also be found on our website here https://www.physiomics.co.uk/resources/ . In addition, the Company will participate in a number of virtual 1-1 meetings with potential clients and collaborators.

Dr Jim Millen, CEO said : "In these difficult times, it's great to see that lifescience companies can find creative ways to continue to develop the relationships needed to fight COVID-19, cancer and other diseases where new treatments are desperately needed. We look forward to fully participating in the digital version of this popular conference."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models and its Virtual Tumour(TM) technology to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAKKFBQNBKDBQB

(END) Dow Jones Newswires

April 28, 2020 09:50 ET (13:50 GMT)

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024